文献速递姑息放疗与转移瘤放疗物理与技术

澳大利亚骨转移单次与多次姑息放疗的使用差异

Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-09-07

该研究基于澳大利亚维多利亚州2012至2017年放疗最小数据集,纳入10,956例患者共18,158疗程骨转移放疗,评估单次姑息放疗(SFRT)的使用情况。结果显示仅17%为SFRT,2012年18%至2017年19%无显著变化(P=.07),且使用率因部位、肿瘤类型、城乡、机构类型等因素而异。结论认为SFRT在澳大利亚骨转移治疗中使用不足且存在实践差异。

要点

  • 骨转移姑息放疗中仅17%为单次放疗,2012至2017年无显著变化(P=.07)。
  • 肩部(37%)和肋骨(53%)SFRT使用率高于颅骨(4%)和脊柱(14%)。
  • 区域/偏远地区(22% vs 16%)和公立机构(22% vs 10%)SFRT使用率更高(P<.001)。

核心结论

  • SFRT在澳大利亚骨转移治疗中使用不足,且存在患者、肿瘤、社会人口学、地理和机构提供者因素相关的实践差异。

研究设计与样本

  • 基于人群的队列研究,纳入2012至2017年维多利亚州放疗最小数据集中因骨转移接受放疗的癌症患者。

主要发现

  • 共18,158疗程骨转移放疗,涉及10,956例患者,其中17%为SFRT。
  • SFRT使用率从2012年18%至2017年19%,无显著变化(P=.07)。
  • 颅骨SFRT使用率4%,脊柱14%,肩部37%,肋骨53%。
  • 肺癌患者SFRT使用率21%,前列腺癌18%,胃肠道癌16%。
  • 区域/偏远地区较主要城市SFRT使用率更高(22% vs 16%,P<.001),公立机构较私立更高(22% vs 10%,P<.001)。

关键数值与推荐

  • 多变量分析显示,年龄增加、肺癌、较高社会经济地位、居住于区域/偏远地区及在公立机构治疗与接受SFRT的可能性增加独立相关。

临床怎么用

  • 临床中应关注骨转移SFRT的使用不足,并针对可干预因素优化放疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the use of single-fraction palliative radiation therapy (SFRT) for the management of bone metastases (BM) in Victoria, Australia. METHODS AND MATERIALS: This is a population-based cohort of patients with cancer who received radiation therapy for BM between 2012 and 2017 as captured in the Victorian Radiotherapy Minimum Data Set. The primary outcome was proportion of SFRT use. The Cochrane-Armitage test for trend was used to evaluate changes in practice over time. Multivariable logistic regression was used to assess factors associated with SFRT use. RESULTS: Of the 18,158 courses of radiation therapy for BM delivered to a total of 10,956 patients, 17% were SFRT. There was no significant change in SFRT use over time, from 18% in 2012 to 19% in 2017 (P = .07). SFRT was less commonly given to the skull (4%) and spine (14%), compared with the shoulder (37%) and ribs (53%). Patients with lung cancer (21%) were most likely to receive SFRT, followed by those with prostate cancers (18%) and gastrointestinal cancers (16%). Patients from regional/remote areas were more likely to have SFRT compared with those in major cities (22% vs 16%, P < .001). Patients treated in public institutions were more likely to have SFRT compared with those treated in private institutions (22% vs 10%, P < .001). In multivariable analyses, increasing age, lung cancer, higher socioeconomic status, residence in regional/ remote areas, and being treated in public institutions were factors independently associated with increased likelihood of receiving SFRT. CONCLUSIONS: SFRT appears underused for BM in Australia over time, with variation in practice by patient, tumor, sociodemographic, geographical, and institutional provider factors.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ong WL, Foroudi F, Milne RL, et al. Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia. Int J Radiat Oncol Biol Phys. 2019. PMID: 31505246. doi:10.1016/j.ijrobp.2019.08.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。